About Monoclonal Antibodies
Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell. They are complex proteins with high molecular weight, and were first developed in 1975 by Kohler and Milstein.
Technavio’s analysts forecast the global monoclonal antibodies (mAbs) market to grow at a CAGR of 9.84% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded mAbs and biosimilars used to treat cancer, autoimmune and inflammatory diseases, respiratory diseases, and ophthalmology. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market, along with the decline in revenues from the patent expiries of the marketed drugs, during the forecast period.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Monoclonal Antibodies (mAbs) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AbbVie
• Amgen
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Johnson & Johnson
• Merck
Other prominent vendors
• AbGenomics
• ADC Therapeutics
• Agensys
• Alexion Pharmaceuticals
• ALMAC Group
• Ambrx
• Astellas Pharma
• AstraZeneca
• Bayer HealthCare
• Biogen
• Celgene
• Celldex Therapeutics
• Daiichi Sankyo
• Eisai
• Eli Lilly
• Formation Biologics
• Genmab
• GlaxoSmithKline
• Human Genome Sciences
• Immunogen
• MedImmune
• Novartis
• Pfizer
• Seattle Genetics
• Stemcentrx
• Synthon Biopharmaceuticals
• Takeda Pharmaceuticals
• Teva
• UCB
Market driver
• Special regulatory drug designations
• For a full, detailed list, view our report
Market challenge
• High manufacturing costs coupled with stringent regulations
• For a full, detailed list, view our report
Market trend
• Growing focus of vendors on untapped markets
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: mAbs: Overview
• Evolution of mAb therapeutics
• Types of mAbs
• Conjugated cancer therapies using mAbs
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Market segmentation by type of mAbs
• Naked mAbs
• Conjugated mAbs
PART 08: Market segmentation by application
• Global oncology mAbs market
• Global autoimmune and inflammatory mAbs market
• TNF inhibitors
• IL-1 blockers
• PDE4 inhibitors
• Global respiratory mAbs market
• Global ophthalmology mAbs market
PART 09: Geographical segmentation
• Global mAbs market by geographical segmentation 2015-2020
• mAbs market in Americas
• mAbs market in US
• mAbs market in EMEA
• mAbs market in APAC
PART 10: Key leading countries
PART 11: Pipeline portfolio
PART 12: Market drivers
• Reimbursement benefits for mAbs and its biosimilars
• Special regulatory drug designations
• Increase in demand for ADCs
• Increase in industry-academia collaborations
PART 13: Impact of drivers
PART 14: Market challenges0
• Absence of adequate diagnosis and screening procedures
• High manufacturing costs coupled with stringent regulations
• Threat from chemotherapy and off-label drugs
• Difficulties in patient recruitment for conducting clinical trials
PART 15: Impact of drivers and challenges
PART 16: Market trends
• Emergence of biosimilars
• Growing focus of vendors on untapped markets
• Focus on novel mechanisms
• Joint ventures and partnerships for R&D
• Emergence of targeted and combination therapies
PART 17: Vendor landscape
• Competitive scenario
• Key news
• F. Hoffmann-La Roche
• AbbVie
• Johnson & Johnson
• Amgen
• Merck
• BMS
• Other prominent vendors
PART 18: Appendix
• List of abbreviations
PART 19: Explore Technavio
?
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for mAbs 2015
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Comparison of small molecule and mAbs
Exhibit 05: Preparation of mAbs
Exhibit 06: Types of mAbs
Exhibit 07: Targeted mechanisms of cancer mAbs
Exhibit 08: Patent expiries of top selling mAbs by 2020 in US
Exhibit 09: Patent expiries of top selling mAbs by 2020 in Europe
Exhibit 10: Global mAbs market snapshot: Developed and emerging markets 2015
Exhibit 11: Global mAbs market 2015-2020 ($ billions)
Exhibit 12: Few patient assistance programs offered by various companies
Exhibit 13: Few awareness programs for various cancers, respiratory, and ophthalmology diseases
Exhibit 14: Impact of drivers and challenges on global mAbs market
Exhibit 15: Competitive assessment of marketed and late-stage pipeline molecules
Exhibit 16: Opportunities in mAbs industry today
Exhibit 17: Five forces analysis
Exhibit 18: Approved naked mAbs by US FDA and EU
Exhibit 19: Global mAbs market: Segmentation by application (2015-2020)
Exhibit 20: Global mAbs market: Segmentation by application 2015
Exhibit 21: Global mAbs market segmentation: Growth cycle analysis
Exhibit 22: Annual treatment cost per patient for various oncology drugs 2014
Exhibit 23: Global oncology mAbs market 2015-2020 ($ billions)
Exhibit 24: Opportunity analysis of global oncology mAbs market by type of application
Exhibit 25: Market segmentation by MOA
Exhibit 26: Population aged 60 years and over (millions)
Exhibit 27: Average annual treatment cost of adalimumab, etanercept, and infliximab 2014 ($ millions)
Exhibit 28: Global autoimmune and inflammatory mAbs market 2015-2020 ($ billions)
Exhibit 29: Opportunity analysis of global autoimmune and inflammatory mAbs market by application
Exhibit 30: Global autoimmune and inflammatory mAbs market segmentation by MOA
Exhibit 31: Average percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 32: Global autoimmune and inflammatory mAbs market share by MOA 2015
Exhibit 33: Global respiratory mAbs market 2015-2020 ($ billions)
Exhibit 34: Opportunity analysis of global respiratory mAbs market by application
Exhibit 35: Global mAbs market segmentation by application 2015
Exhibit 36: Global ophthalmology mAbs market 2015-2020 ($ billions)
Exhibit 37: Opportunity analysis of global ophthalmology mAbs market by application
Exhibit 38: Global mAbs market: Geography outlook (2015-2020)
Exhibit 39: Global mAbs market: Geography outlook 2015
Exhibit 40: Revenue/growth outlook in different countries/regions 2015
Exhibit 41: mAbs market in Americas 2015-2020 ($ billions)
Exhibit 42: mAbs market in Americas by country 2015
Exhibit 43: mAbs market in US 2015-2020 ($ billions)
Exhibit 44: mAbs market in EMEA 2015-2020 ($ billions)
Exhibit 45: mAbs market in EMEA by country 2015
Exhibit 46: Number of individuals treated with Herceptin through patient assistance programs in China
Exhibit 47: mAbs market in APAC 2015-2020 ($ billions)
Exhibit 48: mAbs market in APAC by country 2015
Exhibit 49: Global mAbs market by geographical segmentation 2015
Exhibit 50: Global mAbs market by geographical segmentation 2020
Exhibit 51: Global mAbs market revenue by geography 2015-2020 ($ billions)
Exhibit 52: Key leading countries
Exhibit 53: Pipeline share of global mAbs market 2015
Exhibit 54: Phase III pipeline molecules for mAbs
Exhibit 55: Phase II pipeline molecules for mAbs
Exhibit 56: Phase I pipeline molecules for mAbs
Exhibit 57: Special regulatory designations approved by US FDA
Exhibit 58: Special regulatory designations approved by EU
Exhibit 59: Impact of drivers
Exhibit 60: Impact of drivers and challenges
Exhibit 61: Expected combination regimen launches in oncology
Exhibit 62: Global mAbs market: Impact assessment of top trends 2015
Exhibit 63: Market presence of vendors in various therapy areas 2015
Exhibit 64: Market share analysis 2015
Exhibit 65: YoY sales comparison of top ten mAbs 2013-2015 ($ billions)
Exhibit 66: Competitive assessment of vendors
Exhibit 67: Key vendors: Geographical presence 2015
Exhibit 68: F. Hoffmann-La Roche: YoY growth and revenue of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 69: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 70: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
Exhibit 71: F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015
Exhibit 72: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
Exhibit 73: F. Hoffmann-La Roche: Geographical segmentation of Herceptin 2015
Exhibit 74: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Lucentis 2013-2015 ($ billions)
Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
Exhibit 76: F. Hoffmann-La Roche: Geographical segmentation of Perjeta 2015
Exhibit 77: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Xolair 2013-2015 ($ billions)
Exhibit 78: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 79: F. Hoffmann-La Roche: Geographical segmentation of Kadcyla 2015
Exhibit 80: Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 81: Actemra/RoActemra geographic segmentation by revenue 2015
Exhibit 82: F Hoffmann-La Roche: Metrics analysis
Exhibit 83: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
Exhibit 84: AbbVie: YoY revenue and growth rate of Humira (US) 2013-2015 ($ billions)
Exhibit 85: AbbVie: YoY revenue and growth rate of Humira (ROW) 2013-2015 ($ billions)
Exhibit 86: AbbVie: YoY revenue and growth rate of Synagis 2013-2015 ($ millions)
Exhibit 87: AbbVie: Metrics analysis
Exhibit 88: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2015 ($ billions)
Exhibit 89: Johnson & Johnson: YoY growth rate and revenue of Remicade (US) 2013-2015 ($ billions)
Exhibit 90: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2013-2015 ($ billions)
Exhibit 91: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
Exhibit 92: Johnson & Johnson: YoY growth rate and revenue of Stelara (US) 2013-2015 ($ millions)
Exhibit 93: Johnson & Johnson: YoY growth rate and revenue of Stelara (ROW) 2013-2015 ($ millions)
Exhibit 94: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2013-2015 ($ millions)
Exhibit 95: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (US) 2013-2015 ($ millions)
Exhibit 96: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2013-2015 ($ millions)
Exhibit 97: Johnson & Johnson: Metrics analysis
Exhibit 98: Amgen: YoY growth and revenue generated from net product sales of Xgeva 2013-2015 ($ billions)
Exhibit 99: Amgen: Geographic segmentation of Xgeva 2015
Exhibit 100: Amgen: YoY growth and revenue generated from net product sales of Prolia 2013-2015 ($ billions)
Exhibit 101: Amgen: Geographical segmentation of Prolia 2015
Exhibit 102: Amgen: YoY growth and revenue generated from net product sales of Vectibix 2013-2015 ($ millions)
Exhibit 103: Amgen: Geographical segmentation of Vectibix 2015
Exhibit 104: Amgen: Metrics analysis
Exhibit 105: Merck: YoY revenue and growth rate of Remicade (Europe, Russia, and Turkey) 2013-2015 ($ billions)
Exhibit 106: Merck: YoY revenue and growth rate of Simponi (Europe, Russia, and Turkey) 2013-2015 ($ millions)
Exhibit 107: Merck: Metrics analysis
Exhibit 108: BMS: YoY growth and revenue generated from net product sales of Yervoy 2011-2014 ($ billions)
Exhibit 109: BMS: Geographical segmentation of Yervoy 2015
Exhibit 110: BMS: YoY Revenue and growth rate of Erbitux in US and Canada 2013-2015 ($ millions)
Exhibit 111: BMS: Geographical segmentation of Yervoy 2015
Exhibit 112: BMS: Geographical segmentation of Opdivo 2015
Exhibit 113: BMS: Metrics analysis
